Clinical trials update: Highlights of the scientific sessions of the American College of Cardiology 2002: LIFE, DANAMI 2, MADIT-2, MIRACLE-ICD, OVERTURE, OCTAVE, ENABLE 1 & 2, CHRISTMAS, AFFIRM, RACE, WIZARD, AZACS, REMATCH, BNP trial and HARDBALL

European Journal of Heart Failure

Volumn 4, Issue 3, 2002, Pages 381-388

  Coletta, Alison ^a   Thackray, Simon ^a   Nikitin, Nikolay ^a   Cleland, John G F ^a  

^a CASTLE HILL HOSPITAL   (United Kingdom)

Author keywords

AFFIRM; AZACS; BNP trial; CHRISTMAS; DANAMI 2; ENABLE 1 2; HARDBALL; LIFE; MADIT 2; MIRACLE ICD; OCTAVE; OVERTURE; RACE; REMATCH; WIZARD

Indexed keywords

ALTEPLASE; AMIODARONE; ANTIARRHYTHMIC AGENT; ATENOLOL; AZITHROMYCIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENDOTHELIN RECEPTOR ANTAGONIST; LOSARTAN; OMAPATRILAT; PLACEBO; SOTALOL;

ANGIONEUROTIC EDEMA; ARTERIAL PRESSURE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVERSION; CLINICAL FEATURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DILATATION; COUGHING; DEFIBRILLATOR; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; ELECTROCARDIOGRAM; EXERCISE; FIBRINOLYTIC THERAPY; FUNCTIONAL ASSESSMENT; GLUCOSE BLOOD LEVEL; HEART ASSIST DEVICE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART TRANSPLANTATION; HOSPITALIZATION; HUMAN; HYPERTENSION; META ANALYSIS; PHYSICAL CAPACITY; PRIORITY JOURNAL; QUALITY OF LIFE; REVASCULARIZATION; REVIEW; SIDE EFFECT; SURVIVAL RATE; THROMBOEMBOLISM; TREATMENT OUTCOME;

CARDIOLOGY; CLINICAL TRIALS; HEART FAILURE, CONGESTIVE; HUMANS; SOCIETIES, MEDICAL; UNITED STATES;

EID: 0036623832     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(02)00040-5     Document Type: Review

References (14)

1. Dahlof B, Devereux RB, Kjeldsen SE, et al. for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
2. Lindholm LH, Ibsen H, Dahlof B, et al. for the LIFE study group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-10.
3. Moss AJ, Zareba W, Hall J, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346(12):877-83.
4. Bigger JT. Expanding indications for implantable cardiac defibrillators. N Engl J Med 2002;346(12):931-3.
5. Cleland JGF, Thackray S, Goodge L, Kaye G, Cooklin M. Outcome studies with device therapy in patients with heart failure. J Cardiovasc Electrophysiol 2002;13:S73-91.
6. Grimm W, Hoffmann JJ, Muller HH, Maisch B. Implantable defibrillator event rates in patients with idiopathic dilated cardiomyopathy, nonsustained ventricular tachycardia on Holter and a left ventricular ejection fraction below 30%. J Am Coll Cardiol, Mar 6 2002;39(5):780-7.
7. Louis A, Cleland JGF, Crabbe S, Ford S, Thackray S, Houghton T, Clark A. Clinical trials update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER, RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology 2001. Eur J Heart Fail 2001;3:381-7.
8. Boehmer JP, DeMarco T, Jaski BE, Carlsen MD, Rathbun VL, Schmeichel CN. Why ICD patients with heart failure (Class II-IV) are hospitalized: Do the reasons differ for patients who are treated with cardiac resynchronisation therapy? JACC 2002;39:159A.
9. Thackray S, Coletta A, Jones P, Dunn A, Clark AL, Cleland JGF. Clinical trials update: Highlights of the Scientific Sessions of Heart Failure 2001, a meeting of the Working Group on Heart Failure of the European Society of Cardiology. CONTAK-CD, CHRISTMAS, OPTIME-CHF. Eur J Heart Fail 2001;3:491-4.
10. Packer M, Poole Wilson PA, Armstrong PW, et al. on behalf of the ATLAS investigators. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999;100:2312-8.
11. Cleland JGF, Pennell DJ, Ray S, et al. and The CHRISTMAS Study Steering Committee and Investigators, The Carvedilol Hibernation Reversible Ischaemia Trial: marker of success (CHRISTMAS). Eur J Heart Fail 1999;1:191-6.
12. Cowburn PJ, Cleland JGF, Coats AJS, Komajda M. Risk stratification in chronic heart failure. Eur Heart J 1998;19:696-710.
13. Khand A, Rankin AC, Kaye GC, Cleland JGF. Systematic review of the management of atrial fibrillation in patients with heart failure. Eur Heart J 2000;21:614-32.
14. Rose EA, Gelijns AC, Moskowitz AJ, et al. for the randomised evaluation of mechanical assistance for the treatment of congestive heart failure (REMATCH) study group. Long term use of a left ventricular assist device for end-stage heart failure. N Eng J Med 2001;345:1435-43.